BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 26, 2008
View Archived Issues
Studies show surfen to be a heparan sulfate antagonist
Read More
Merck & Co reports results from studies with cathepsin K inhibitor odanacatib
Read More
Recent patents report novel therapeutic agents for HCV infection
Read More
New anticancer agents described in recent patents
Read More
Kaken launches new formulation Adofeed Pap 80 mg in Japan
Read More
Novel agents for respiratory and allergic disorders disclosed in recent patent literature
Read More
New antiviral drug company formed, Cocrystal Discovery
Read More
Omrix enrolls initial 90 patients for interim analysis in Fibrin Pad phase II trial
Read More
Paion presents update on phase I CNS-7056 study
Read More
SciClone presents promising phase II results for SCV-07 in hepatitis C
Read More
Clinical data for rheumatoid arthritis drug candidate VEL-0230 presented
Read More
Akesis expands preclinical safety program for AKP-020
Read More
Novel TNF-alpha antagonists developed at Ensemble Discovery
Read More
Athersys provides update on ATHX-105 development and results of recent studies
Read More
Preliminary results for AMG-386 in combination with other antiangiogenic agents in solid tumors
Read More
Belinostat in combination with carboplatin and paclitaxel evaluated in phase I/II cancer studies
Read More
Cornerstone initiates CPI-613 trial for the treatment of cancer
Read More
Metabasis initiates MB-07803 trial in patients with type 2 diabetes
Read More
Oramed commences phase IIa oral insulin trials in patients with type 1 diabetes
Read More
PolyMedix starts dosing in phase I novel anticoagulant antagonist trial
Read More
Baxter initiates phase III Gammagard Liquid trial for the treatment of AD
Read More
MAA for lacosamide in diabetic neuropathic pain withdrawn; product launched in E.U. for seizures
Read More
CHMP issues positive opinion for Kuvan for hyperphenylalaninemia
Read More
Abstral receives U.K. marketing authorization for breakthrough cancer pain
Read More
Aveo initiates first SCH-900105 trial in patients with solid tumors and lymphomas
Read More